TSP has been a certified GMP pharmaceutical manufacturer since 1990 with certification for 11 kinds of dosage forms. To date, the company has already produced and marketed 105 items for distribution domestically and 43 items for export. TSP’s production activities are carried out at its 11,622 sq metres plant in Cawang, East Jakarta. Its factory was recently upgraded and it has a work force of 945.
Tablet capacity is by far the largest compared to the capsule and liquid lines. The table line is currently running at 90% utilisation based on one extended shift per day. The table capacity is primarily devoted to the production of the Bode lines. Total tablet production is approximately two billion units per year, while capsules are around 110 million units and liquid, 38 billion bottles. The majority of its capsule machinery is for the production of Hemaviton.
TSP’s strength lies in its OTC products with major brands Brodex, Brodexin, and Hemaviton, collectively, contributing approximately 70% of the consolidated pharmaceutical revenue. These products reportedly generate very high gross margins estimated to be around 60%. Neo-Rheumacyl the largest single product contributor to the ethical product line, contribute around 16% of the consolidated pharmaceutical revenue.
Advertising and promotional activities are very important for successfully marketing OTC products and maintaining brand royalty. TSP allocates approximately 20% of its OTC revenue for this purpose. Although the percentage may seem slightly lower than those of its competitors, this is because most of its OTC products are already very well known in Indonesia.
